IN8bio, Inc. (INAB)
$1.18-4.07%Close
BUYCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $11M
- Beta
- 0.30
- P/E (TTM)
- -0.63
- Short % float
- 0.64%
- Days to cover
- 1.0
- SI change
- -26.4%
- 1W
- -15.11%
- 1M
- +6.31%
- vs SPY 1W
- -14.97%
- vs SPY 1M
- +3.80%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on INAB?
- LOPJLB’s latest quantitative signal on IN8bio, Inc. (INAB) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is INAB in?
- IN8bio, Inc. (INAB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does IN8bio, Inc. (INAB) do?
- IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phas…